Sarepta allowed to continue US Elevidys shipments
It has been a tumultuous two weeks for Sarepta; however, the FDA reauthorising US shipments of Elevidys will be a welcome development.
Cytiva-Cell & Gene Therapy WP 2
CHMP rejects Elevidys in latest setback for Sarepta
Sarepta halts Elevidys shipments following FDA pressure
Sarepta refuses to pull gene therapy despite FDA request
Eli Lilly strikes $1.3bn gene therapy deal with Rznomics
Stylus Medicine launches with $85m to advance in vivo gene editing
Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales
Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline
